Clinical Features and Management of COVID-19–Associated Hypercoagulability

COVID-19 is an acute respiratory disease of viral origin caused by SARS-CoV-2. This disease is associated with a hypercoagulable state resulting in arterial and venous thrombotic events. The latter are more frequent, especially in patients who develop a severe form of the disease and are associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Massaro, Gianluca, Lecis, Dalgisio, Martuscelli, Eugenio, Chiricolo, Gaetano, Sangiorgi, Giuseppe Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556574/
https://www.ncbi.nlm.nih.gov/pubmed/35221084
http://dx.doi.org/10.1016/j.ccep.2021.10.005
_version_ 1784592196216815616
author Massaro, Gianluca
Lecis, Dalgisio
Martuscelli, Eugenio
Chiricolo, Gaetano
Sangiorgi, Giuseppe Massimo
author_facet Massaro, Gianluca
Lecis, Dalgisio
Martuscelli, Eugenio
Chiricolo, Gaetano
Sangiorgi, Giuseppe Massimo
author_sort Massaro, Gianluca
collection PubMed
description COVID-19 is an acute respiratory disease of viral origin caused by SARS-CoV-2. This disease is associated with a hypercoagulable state resulting in arterial and venous thrombotic events. The latter are more frequent, especially in patients who develop a severe form of the disease and are associated with an increased mortality rate. It is therefore essential to identify patients at higher risk to initiate antithrombotic therapy. Hospitalized patients treated with treatment dose of anticoagulants had better outcomes than those treated with prophylactic dose. However, several trials are ongoing to better define the therapeutic and prevention strategies for this insidious complication.
format Online
Article
Text
id pubmed-8556574
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-85565742021-11-01 Clinical Features and Management of COVID-19–Associated Hypercoagulability Massaro, Gianluca Lecis, Dalgisio Martuscelli, Eugenio Chiricolo, Gaetano Sangiorgi, Giuseppe Massimo Card Electrophysiol Clin Article COVID-19 is an acute respiratory disease of viral origin caused by SARS-CoV-2. This disease is associated with a hypercoagulable state resulting in arterial and venous thrombotic events. The latter are more frequent, especially in patients who develop a severe form of the disease and are associated with an increased mortality rate. It is therefore essential to identify patients at higher risk to initiate antithrombotic therapy. Hospitalized patients treated with treatment dose of anticoagulants had better outcomes than those treated with prophylactic dose. However, several trials are ongoing to better define the therapeutic and prevention strategies for this insidious complication. Elsevier Inc. 2022-03 2021-10-30 /pmc/articles/PMC8556574/ /pubmed/35221084 http://dx.doi.org/10.1016/j.ccep.2021.10.005 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Massaro, Gianluca
Lecis, Dalgisio
Martuscelli, Eugenio
Chiricolo, Gaetano
Sangiorgi, Giuseppe Massimo
Clinical Features and Management of COVID-19–Associated Hypercoagulability
title Clinical Features and Management of COVID-19–Associated Hypercoagulability
title_full Clinical Features and Management of COVID-19–Associated Hypercoagulability
title_fullStr Clinical Features and Management of COVID-19–Associated Hypercoagulability
title_full_unstemmed Clinical Features and Management of COVID-19–Associated Hypercoagulability
title_short Clinical Features and Management of COVID-19–Associated Hypercoagulability
title_sort clinical features and management of covid-19–associated hypercoagulability
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556574/
https://www.ncbi.nlm.nih.gov/pubmed/35221084
http://dx.doi.org/10.1016/j.ccep.2021.10.005
work_keys_str_mv AT massarogianluca clinicalfeaturesandmanagementofcovid19associatedhypercoagulability
AT lecisdalgisio clinicalfeaturesandmanagementofcovid19associatedhypercoagulability
AT martuscellieugenio clinicalfeaturesandmanagementofcovid19associatedhypercoagulability
AT chiricologaetano clinicalfeaturesandmanagementofcovid19associatedhypercoagulability
AT sangiorgigiuseppemassimo clinicalfeaturesandmanagementofcovid19associatedhypercoagulability

Ejemplares similares